What is ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study?

Category: Others

false

See also: Cyclophosphamide Rituximab

ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study is a randomized, double Blind controlled trial comparing rituximab against cyclophosphamide in patients with connective tissue disease associated interstitial lung disease. NCT01862926

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 1
Moderate 4
Mild 0
None 3

Commonly reported side effects and conditions associated with ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study

Side effect Patients
Dizziness and feeling faint 1
Fatigue 1
Muscle pain 1
Muscle tightness 1
Nausea 1

Why patients stopped taking ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped using ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study

Duration

Stopped using ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study

Duration Patients
1 - 6 months 1
Adherence
Adherence Evaluations
Always 8
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 7

What people switch to and from

Patients started using ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study after stopping:

Treatment Patients
Methylprednisolone (Solu-Medrol Infusion) 1
Last updated:
There are no evaluations for ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study.